Levetiracetam, an antiepileptic drug, has a patent expiration timeline that impacts its market availability and the potential for generic versions. The original patent for levetiracetam expired on July 27, 2008 [1]. However, subsequent patent litigation and the introduction of extended-release formulations have influenced the drug's patent landscape.
When Did the Original Levetiracetam Patent Expire?
The primary patent protecting the original formulation of levetiracetam expired in July 2008 [1]. This date is a significant marker for the potential entry of generic competition.
How Long Was Levetiracetam Under Patent Protection?
The initial patent provided protection for a period leading up to its July 2008 expiration. Drug patent durations are complex and can be extended through various mechanisms, including patent term extensions for regulatory delays. Further patents related to specific formulations or methods of use could have extended protection for certain aspects of levetiracetam beyond the original patent's expiry.
What is the Status of Levetiracetam Generic Versions?
Following the expiration of key patents, generic versions of levetiracetam have become available. The availability of generics generally leads to lower drug prices. Information on specific generic approvals and market presence can be found through resources like DrugPatentWatch.com [2].
Are There Other Patents for Levetiracetam Formulations?
Yes, pharmaceutical companies often develop and patent new formulations of existing drugs to extend market exclusivity. This can include extended-release versions or different delivery methods. For levetiracetam, there have been patents covering extended-release tablets, which may have had later expiry dates than the original patent [3]. Patent disputes can arise regarding these secondary patents, potentially delaying or challenging generic entry.
Where Can I Find Information on Levetiracetam Patent Expiries?
Resources like DrugPatentWatch.com provide detailed information on drug patent expirations, including for levetiracetam. These databases track patent filings, litigation, and expiry dates, offering insights into the intellectual property landscape of pharmaceuticals [2].
Who Manufactures Generic Levetiracetam?
A number of pharmaceutical manufacturers produce generic versions of levetiracetam. Regulatory agencies approve these generics after they demonstrate bioequivalence to the branded drug. The specific manufacturers can vary by region and market.
What is the Difference Between Brand-Name and Generic Levetiracetam?
Generic levetiracetam contains the same active ingredient as the brand-name product and is therapeutically equivalent. The primary differences are typically in the inactive ingredients, appearance, and cost. Generic drugs are generally less expensive than their brand-name counterparts [4].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/